CARotid plaqUe StabilizatiOn and Regression With Evolocumab.

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2021

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
The CARUSO trial aims at investigating the efficacy of evolocumab in promoting carotid plaque morphological stabilization and regression as compared to traditional lipid lowering therapy (LLT). Primary end-point of the study is the superiority of evolocumab on top of ongoing LLT versus ongoing LLT in carotid plaque morphological stabilization and regression at 6 and 12 months, respectively. Secondary end-points are: LDL-Cholesterol (LDL-C) absolute and percentage changes in the two groups at 12 month follow-up, and adverse cerebrovascular and cardiac events at 12 and 24 months
Epistemonikos ID: e3c3a32a8a3ad455dab72387f4a6a9f9820b6e38
First added on: May 08, 2024